Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVX-508 in Sickle Cell Disease
NCT03013426Phase 1Withdrawn
- Sponsor
- Amma Owusu-Ansah
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of NVX-508 in sickle cell disease (SCD), sponsored by Amma Owusu-Ansah. Primary endpoint: Maximum Tolerated Dose at 1 year. Planned start Jul 2018; status: withdrawn.
02
Drugs
NVX-508
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03013426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013426.